TMDX | NASDAQ
Next Earnings: Jun 29, 2026
Company Overview:
7.2 Year TMDX Performance Metrics:
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]TMDX Earnings, Revenue, Cash & Debt, Shares Outstanding:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for TMDX
Based on past 7.2-year performance, here are TMDX growth metrics:
Share price CAGR of +16.53%
Dividend CAGR of +0%
Using TMDX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| TMDX (DRIP) | TMDX - No DRIP | |
|---|---|---|
| Current Price | $67.27 | $67.27 |
| Start Shares | 148.65 | 148.65 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 148.65 | 148.65 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $310.60 | $67.27 |
| Total Dividends | $0 | $0 |
| Final Value | $46,172 | $10,000 |
NOTE: Above numbers are our estimate based on TMDX's Dividend and Price CAGR over past 7.2 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
TransMedics Group, Inc. (TMDX) had its IPO on 2019-05-02, and is trader on NASDAQ stock exchange.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX website: https://www.transmedics.com
